Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP45: Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosisECCO'22
Year: 2022
Authors: Armuzzi, A.(1);Cross, R.K.(2);Lichtenstein, G.(3);Calkwood, J.(4);Pai, A.(5);Pondel, M.(5);Ahmad, H.A.(5);Charles, L.(5);Elegbe, A.(5);Petersen, A.(5);Sheffield, J.K.(5);Javed, A.(6);Hou, J.(7);Regueiro, M.(8);Wolf, D.C.(9);Long, M.(10);
(1)Fondazione Policlinico A. Gemelli IRCCS- Catholic University of Rome, Gastroenterology, Rome, Italy;(2)University of Maryland School of Medicine, Gastroenterology, Baltimore, United States;(3)University of Pennsylvania, Gastroenterology, Philadelphia, United States;(4)Minneapolis Clinic of Neurology, Neurology, Minneapolis, United States;(5)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(6)University of Chicago, Neurology, Chicago, United States;(7)Baylor College of Medicine, Gastroenterology, Houston, United States;(8)Cleveland Clinic, Gastroenterology, Cleveland, United States;(9)Atlanta Gastroenterology Associates, Gastroenterology, Atlanta, United States;(10)UNC Chapel Hill, Gastroenterology, Chapel Hill, United States;
DOP46: Metabolic adaptation to ER stress licences STING signalling in intestinal epithelial cellsECCO'22
Year: 2022
Authors: Wottawa, F.(1);Becker, B.(2);Bakr, M.(1);Kugler, J.(1);Mayr, L.(3);Paludan, S.(4);Blumberg, R.(5);Kaser, A.(6);Adolph, T.(3);Schreiber, S.(7);Meiser, J.(2);Rosenstiel, P.(1);Aden, K.(7);
(1)University Medical Center Schleswig-Holstein Kiel, Institute of Clinical Molecular Biology, Kiel, Germany;(2)Luxembourg Institute of Health, Department of Oncology, Luxembourg, Luxembourg;(3)Medical University of Innsbruck, Department of Internal Medicine I- Gastroenterology- Hepatology- Metabolism & Endocrinology, Innsbruck, Austria;(4)Aarhus University, Department of Biomedicine, Aarhus, Denmark;(5)Brigham and Women’s Hospital- Harvard Medical School, Gastroenterology Division- Department of Medicine, Boston, United States;(6)Addenbrooke’s Hospital- University of Cambridge, Department of Medicine, Cambridge, United Kingdom;(7)University Medical Center Schleswig-Holstein Kiel, Department of Medicine I, Kiel, Germany;
DOP47: Identification and characterization of T-cell receptor sequences associated with Crohn’s DiseaseECCO'22
Year: 2022
Authors: Pesesky, M.(1);Carty, C.L.(1);Singh, N.(2);Le Bourhis, L.(3);Rosati, E.(4);Bokemeyer, B.(5);Schreiber, S.(4);Görg, S.(6);Gittelman, R.M.(1);Dines, J.N.(2);Kaplan, I.M.(7);Zahid, H.J.(8);Baldo, L.(2);Snyder, T.M.(1);Robins, H.S.(1);Franke, A.(4);Allez, M.(3);
(1)Adaptive Biotechnologies, Innovation, Seattle, United States;(2)Adaptive Biotechnologies, Medical Affairs and Clinical Development, Seattle, United States;(3)Hôpital Saint-Louis, Hepato-Gastero-Enterologie, Paris, France;(4)Christian-Albrecht University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany;(5)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis, Minden, Germany;(6)University Hospital of Schleswig-Holstein, Institute for Transfusion Medicine, Kiel, Germany;(7)Adaptive Biotechnologies, Partnerships, Seattle, United States;(8)Microsoft Research, Immunomics, Redmond, United States;
DOP48: Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBDECCO'22
Year: 2022
Authors: Hanna, J.(1);Beke, F.(2);O'Brien, L.(2);Kapeni, C.(2);Chen, H.C.(2);Carbonaro, V.(2);Kim, A.(3);Kishore, K.(2);Adolph, T.E.(4);Skjoedt, M.O.(5);Skjoedt, K.(6);de la Roche, M.(7);de la Roche, M.(2);
(1)University of Cambridge, Cancer Research UK - Cambridge Institute / School of Clinical Medicine, Cambridge, United Kingdom;(2)University of Cambridge, Cancer Research UK - Cambridge Institute, Cambridge, United Kingdom;(3)Washington University in St. Louis, Washington University School of Medicine, St. Louis, United States;(4)Medical University Innsbruck, Department of Internal Medicine I- Gastroenterology- Hepatology & Endocrinology, Innsbruck, Austria;(5)University of Copenhagen, Institute of Immunology and Microbiology, Copenhagen, Denmark;(6)University of Southern Denmark, Department of Cancer and Inflammation Research, Odense, Denmark;(7)University of Cambridge, Department of Biochemistry, Cambridge, United Kingdom;
DOP49: Context-dependent roles of High-mobility group box 1 (HMGB1) during intestinal inflammation and carcinogenesisECCO'22
Year: 2022
Authors: Zierz, E.(1);Foelsch, K.(1);Pelczar, P.(1);Qi, M.(2);Alawi, M.(2);Clauditz, T.(3);Gagliani, N.(4);Huber, S.(1);Huebener, P.(1);
(1)University Medical Center Hamburg-Eppendorf, I. Department of Medicine, Hamburg, Germany;(2)University Medical Center Hamburg-Eppendorf, Bioinformatics Core Facility, Hamburg, Germany;(3)University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany;(4)University Medical Center Hamburg-Eppendorf, Department of General- Visceral and Thoracic Surgery, Hamburg, Germany;Huebener
DOP50: Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primatesECCO'22
Year: 2022
Authors: Wong, J.(1);Lee, D.(2);Mangada, M.(3);Yadav, V.(3);Troast, D.(4);Zhong, C.(4);Hahn, K.(4);Wang, W.(5);Ge, X.(5);Sun, L.(5);Jiang, S.(5);Wang, B.(5);Zhang, J.(5);Yan, L.(5);Nguyen, H.(6);Cui, D.(2);Bursavich, M.G.(4);Lippa, B.(4);Rogers, B.N.(7);Ray, A.S.(8);
(1)Morphic Therapeutic, Biology, Waltham -Massachusetts, United States;(2)Morphic Therapeutic, Drug Metabolism PharmacoKinetics, Waltham -Massachusetts, United States;(3)Morphic Therapeutic, Translational Sciences, Waltham -Massachusetts, United States;(4)Morphic Therapeutic, Chemistry, Waltham -Massachusetts, United States;(5)ChemPartner, Biology, Shanghai, China;(6)Morphic Therapeutic, Chemistry Manufacturing and Controls, Waltham -Massachusetts, United States;(7)Morphic Therapeutic, Biology- Translational Sciences- and Chemistry, Waltham -Massachusetts, United States;(8)Morphic Therapeutic, Biology and Translational Sciences, Waltham -Massachusetts, United States;
DOP51: Loss of PTPN23 in the intestinal epithelium results in epithelial hyperproliferation and lethal diarrhea in a microbiota dependent mannerECCO'22
Year: 2022
Authors: Spalinger, M.(1);Sanchez Alvarez, R.(1);Gottier, C.(1);Montalban-Arques, A.(1);Schwarzfischer, M.(1);Niechcial, A.(1);Scharl, M.(1);
(1)University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;
DOP52: Development of a host-microbe interaction workflow to reveal the cell- and condition-specific effects of a commensal bacteria upon IBDECCO'22
Year: 2022
Authors: Potari-gul, L.(1);Modos, D.(1,2);Fonseca, S.(2);Madgwick, M.(1,2);Thomas, J.P.(1,3);Sudhakar, P.(1,2,4);Booth, C.(5);Stentz, R.(2);Carding, S.R.(2,6);Korcsmaros, T.(1,2);
(1)Earlham Institute- Norwich Research Park, Organisms and Ecosystems, Norwich, United Kingdom;(2)Quadram Institute Bioscience- Norwich Research Park, Gut Microbes and Health Programme, Norwich, United Kingdom;(3)Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom;(4)Translational Research Center for Gastrointestinal Disorders TARGID, KU Leuven Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium;(5)Quadram Institute Bioscience- Norwich Research Park, Core Science Resources, Norwich, United Kingdom;(6)University of East Anglia, Norwich Medical School, Norwich, United Kingdom;
DOP53: In-depth characterisation of the serum antibody epitope repertoire in Inflammatory Bowel Disease by high-throughput phage-displayed immunoprecipitation sequencingECCO'22
Year: 2022
Authors: Bourgonje, A.R.(1);Andreu-Sánchez, S.(2,3);Vogl, T.(4,5);Hu, S.(1,2);Vich Vila, A.(1,2);Leviatan, S.(4,5);Kurilshikov, A.(2);Klompus, S.(4,5);Kalka, I.N.(4,5);van Dullemen, H.M.(1);Weinberger, A.(4,5);Visschedijk, M.C.(1);Festen, E.A.M.(1);Faber, K.N.(1);Wijmenga, C.(2);Dijkstra, G.(1);Segal, E.(4,5);Fu, J.(2,3);Zhernakova, A.(2);Weersma, R.K.(1);
(1)University of Groningen- University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University of Groningen- University Medical Center Groningen, Genetics, Groningen, The Netherlands;(3)University of Groningen- University Medical Center Groningen, Pediatrics, Groningen, The Netherlands;(4)Weizmann Institute of Science, Computer Science and Applied Mathematics, Rehovot, Israel;(5)Weizmann Institute of Science, Molecular Cell Biology, Rehovot, Israel;
DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tractECCO'22
Year: 2022
Authors: Shilova, I.(1);La Chat, C.(1);Nigatu, E.(1);Messner, E.(1);Desnoyer, J.(1);Willcoxon, M.(1);Banas, S.(1);Ravichandar, D.(2);Narayan, N.(2);DeSantis, T.(2);Dabbagh, K.(1);Yamamoto, L.(1);
(1)Second Genome, Discovery, Brisbane, United States;(2)Second Genome, Bioinformatics, Brisbane, United States;
DOP55: Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative ColitisECCO'22
Year: 2022
Authors: Leong, R.(1);Sands, B.(2);Peyrin-Biroulet, L.(3);Marano, C.(4);Miao, Y.(4);Izanec, J.(5);Feagan, B.(6);Rubin, D.(7); UNIFI Investigators
(1)Concord Repatriation General Hospital, Department of Gastroenterology, Concord, Australia;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Nancy University Hospital- Université de Lorraine, Inserm U954 and Department of Gastroenterology, Nancy, France;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Janssen Scientific Affairs- LLC, Immunology, Horsham, United States;(6)Western University and Alimentiv- Inc, Gastroenterology, London, Canada;(7)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;
DOP56: Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn’s DiseaseECCO'22
Year: 2022
Authors: Reinisch, W.(1);De Hertogh, G.(2);Protic, M.(3);Chan, L.S.(3);Magro, F.(4);Pollack, P.(3);Feagan, B.G.(5);Harpaz, N.(6);Pai, R.(7);
(1)Medical University of Vienna, Internal Medicine, Vienna, Austria;(2)KU Leuven, University Hospitals Leuven, Leuven, Belgium;(3)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(4)University Hospital São João, Pharmacology, Porto, Portugal;(5)Robarts Clinical Trials Inc, Medicine- Epidemiology & Biostatistics, London, Canada;(6)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(7)The Mayo Clinic, Gastroenterology, Scottsdale, United States;
DOP57: Development and validation of a convolutional neural network for the automatic detection of enteric ulcers and erosions in capsule endoscopy: A multicentric studyECCO'22
Year: 2022
Authors: Afonso , J.(1);Mascarenhas , M.(1);Ribeiro , T.(1);Cardoso , P.(1);Gonçalves , R.(1);Ferreira , J.(2);Andrade , A.P.(1);Mascarenhas Saraiva , M.(3);Cardoso , H.(1);Macedo , G.(1);
(1)Centro Hospitalar Universitário São João, Gastroenterology, Porto, Portugal;(2)FEUP - Faculdade Engenharia Universidade do Porto, Engenharia, Porto, Portugal;(3)ManoPh Gastroenterology Clinic, Gastroenterology, Porto, Portugal;
DOP58: An artificial intelligence–driven scoring system to measure histological disease activity in Ulcerative ColitisECCO'22
Year: 2022
Authors: Peyrin-Biroulet, L.(1);Adsul, S.(2);Dehmeshki, J.(3);Kubassova, O.(3);
(1)Nancy University Hospital and INSERM U1256 Nutrition-Genetics and Environmental Risk Exposure- Lorraine University, Gastroenterology, Nancy, France;(2)Takeda, Gastroenterology, Zurich, Swaziland;(3)Image Analysis Group, Imaging, London, United Kingdom;
DOP59: Development of a novel Ulcerative Colitis (UC) endoscopic activity prediction model using machine learning (ML)ECCO'22
Year: 2022
Authors: Colombel , J.F.(1);Rubin , D.(2);Schott , J.P.(3);Gottlieb , K.(4);Erisson , L.(5);Prucka , B.(6);Phillips , S.(5);Kwon , J.(7);Ng , J.(8);McGill , J.(4);
(1)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York City- NY, United States;(2)University of Chicago, Gastroenterology, Chicago- IL, United States;(3)Iterative Scopes, Engineering, Cambridge- MA, United States;(4)Eli Lilly and Company, Immunology BU, Indianapolis- IN, United States;(5)Iterative Scopes, Research and Development Strategy, Cambridge- MA, United States;(6)Eli Lilly and Company, Advanced Analytics and Data Sciences, Indianapolis- IN, United States;(7)Gilead Sciences, Immunology, Foster City- CA, United States;(8)Iterative Scopes, Corporate, Cambridge- MA, United States;
DOP60: Self-reported treatment effectiveness for Crohn's Disease using a novel crowdsourcing web-based platformECCO'22
Year: 2022
Authors: Engel, T.(1);Dotan, E.(2);Ben-Horin, S.(1);Kopylov, U.(1);
(1)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(2)Stuffthatworks, Company, Tel Aviv, Israel;
DOP61: Development and validation of novel models in prediction of intravenous corticosteroids resistance in patients with Acute Severe Ulcerative ColitisECCO'22
Year: 2022
Authors: Yu, S.(1);Li, H.(2);Li, Y.(1);Xu, H.(1);Tan, B.(1);Tian, B.(1);Dai, Y.(1);Tian, F.(2);Qian, J.(1);
(1)Peking Union Medical College Hospital, Department of Gastroenterology, Beijing, China;(2)Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang, China;
DOP62: Efficacy of biologic drugs in short-duration versus long-duration Inflammatory Bowel Disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trialsECCO'22
Year: 2022
Authors: Ben-Horin, S.(1,2);Novack, L.(3);Mao, R.(2);Guo, J.(2);Zhao, Y.(2);Sergienko, R.(3);Zhang, J.(2);Kobayashi, K.(4);Hibi, T.(4);Chowers, Y.(5);Peyrin-Biroulet, L.(6);Colombel, J.F.C.(7);Kaplan, G.G.K.(8);Chen, M.H.(2);
(1)Tel-HaShomer Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(2)First affiliated Hospital of the Sun Yatsen University, Gastroenterology, Guangzhou, China;(3)Soroka University Medical Center3- Faculty of Health Sciences- Ben-Gurion University of the Negev-, Clinical research Center, Beer-Sheva, Israel;(4)Kitasato University- Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(5)Rambam Health Care Campus- Bruce & Ruth Rappaport Faculty of Medicine- Technion Institute of Technology, Gastroenterology, Haifa, Israel;(6)Inserm U594- Nancy University Hospital, Gastroenterology, Nancy, France;(7)Icahn School of Medicine- Mount Sinai Hospital, Helmsley Inflammatory Bowel Disease Center, New-York, United States;(8)University of Calgary, Department of Medicine and Community Health Sciences, Calgary, Canada;
DOP63: Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel DiseaseECCO'22
Year: 2022
Authors: Volkers, A.(1);Straatmijer, T.(1);Duijvestein, M.(2);Sales, A.(1);Levran, A.(1);van Schaik, F.(3);Jeroen, M.(4);Gecse, K.(1);Ponsioen, C.(1);Grootjans, J.(1);Hanzel, J.(1);Tack, G.(5);Jansen, J.(6);Hoentjen, F.(7);de Boer, N.(1);van der Marel, S.(8);Dijkstra, G.(9);Oldenburg, B.(3);Löwenberg, M.(1);van der meulen, A.(4);D'Haens, G.(1); on behalf of the IBD center of Amsterdam and the Dutch Initiative on Crohn and Colitis (ICC)
(1)Amsterdam UMC- location AMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(3)University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(4)Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(5)Medical Center Leeuwarden, Department of Gastroenterology and Hepatology, Leeuwarden, The Netherlands;(6)Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)University of Alberta, Division of Gastroenterology- Department of Medicine-, Edmonton, Canada;(8)Haaglanden Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(9)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;
DOP64: Pathogenic RIPK1 Mutations Cause Infantile-onset IBD with Inflammatory and Fistulizing FeaturesECCO'22
Year: 2022
Authors: Sultan, M.(1);Millman, P.(2);McCourt, B.(3);Kol, N.(4);Lev, A.(5);Matar, M.(6);Barel, O.(4);Shamir, R.(6);Wilschanski, M.(2);Konnikova, L.(3);Somech, R.(5);Shouval, D.(6);
(1)Makassed Hospital- Al-Quds University, Pediatric Gastroenteorlogy, Jerusalem, Palestine;(2)Hadassah University Hospital, Pediatric Gastroenterology, Jerusalem, Israel;(3)Yale Medical School, Human and Translational Immunology, New Haven, United States;(4)Sheba Medical Center, The Genomic Unit- Sheba Cancer Research Center and Wohl Institute of Translational Medicine, Ramat Gan, Israel;(5)Edmond and Lily Safra Children’s Hospital, Pediatric Immunology Service- Pediatric Department Ward A and Jeffrey Modell Foundation Center, Ramat Gan, Israel;(6)Schneider Children's Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petah Tiqwa, Israel;